UV1

Phase 2Biologic

UUltimovacs ASA

UV1 is one of 38 biologic programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerRecruiting

Non-Small Cell Lung CancerPhase 2

Recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Taxol

Trodelvy

10 3

Navelbine

PPierre Fabre Medicament

Phase 3

24 4

Remeron

OOrganon and Co

Preclinical

1 5

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—6

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—7

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 9

UV1

UUltimovacs ASA

Phase 2

1 10

PD-1 Inhibitors

BBioNTech US Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Non-Small Cell Lung Cancer

NCT05344209

Clinical

Trials by Indication[1]

Melanoma2 trials

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

Completed·UUltimovacs ASA·Phase 1/2·NCT02275416·12 enrolled

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Completed·UUltimovacs ASA·Phase 2·NCT04382664·156 enrolled

Prostate Cancer1 trial

A Phase I/IIa Study of UV1 Vaccine in Patients With Prostate Cancer

Completed·UUltimovacs ASA·Phase 1/2·NCT01784913·22 enrolled

Small Cell Lung Cancer1 trial

A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.

Completed·UUltimovacs ASA·Phase 1/2·NCT01789099·18 enrolled

Metastatic Melanoma1 trial

UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

Completed·UUltimovacs ASA·Phase 1·NCT03538314·30 enrolled

Non-Small Cell Lung Cancer1 trial

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

Recruiting·VVestre Viken Hospital Trust·Phase 2·NCT05344209·138 enrolled

1 more indication

Head and Neck Squamous Cell Carcinoma1 trial

Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab

Unknown status·MMartin-Luther-Universität Halle-Wittenberg·Phase 2·NCT05075122·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for UV1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UV1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UV1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Ultimovacs ASA company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: UUltimovacs ASA

UV1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Melanoma2 trials

Prostate Cancer1 trial

Small Cell Lung Cancer1 trial

Metastatic Melanoma1 trial

Non-Small Cell Lung Cancer1 trial

Head and Neck Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News